AstraZeneca’s Covid-19 vaccine approved! Here’s what I’d do now

Approval for AstraZeneca’s vaccine brings the UK a step closer to winning the fight against Covid-19. But is there a better investment opportunity than AZN?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca‘s (LSE:AZN) Covid-19 vaccine has been approved for emergency use in the UK this morning.

There had been some confusion surrounding the initial trial dosing regimens and subsequent results. However, the pharmaceutical giant was successful in proving the vaccine is both effective and safe.

What’s next for AstraZeneca?

Working alongside the NHS and other government bodies, AstraZeneca aims to deliver 100 million doses over the next year, with the first batch ready very soon. This is over double the 40 million doses ordered for Pfizer’s vaccine, and over 14 times those ordered for Moderna’s.

I previously wrote that AstraZeneca’s vaccine would become the best choice for the UK and countries worldwide. And I’ve been right so far. You see, despite the higher efficacy of both Pfizer’s and Moderna’s vaccines, they both suffer from a significant disadvantage. They require extraordinary refrigeration of -70°C, and -20°C, respectively, whereas AstraZeneca’s only needs to be kept between 2°C and 8°C. That’s a standard fridge temperature.

Storage facilities in the UK and abroad that can support such sub-zero temperatures are few and far between. This drastically reduces the viability of storage and distribution for Pfizer’s and Moderna’s vaccines, especially in poorer nations.

It’s for this reason that Malaysia has ordered an additional 6.4m doses of AstraZeneca’s vaccine. Furthermore, the company is working closely with its global partners to set up the infrastructure needed to manufacture up to 3bn doses every year.

A hidden gem in the biotech sector

This is undoubtedly fantastic news for AstraZeneca and the public in general. But I won’t be buying shares in the business. Despite the stock being up on the announcement, it’s important to remember that AstraZeneca has stated its vaccine is a no-profit project.

But there’s one stock that greatly benefits from this announcement — Oxford Biomedica (LSE:OXB) — a share that I myself have bought.

The biotech firm specialises in gene and cell therapies. It has been working closely with AstraZeneca throughout the development of the vaccine. The stock offers a proprietary platform called LentiVector, which allows drug developers to pursue new treatments at a fraction of the cost.

In September, Oxford Biomedica signed an 18-month supply agreement with AstraZeneca for its vaccine’s large-scale manufacture. It has already received an initial payment of £15m to get things going and expects to generate another £35m throughout 2021.

The combined additional £45m represents 80% of the firm’s revenue in 2019. After adding the income it makes from its other projects, this agreement will likely double the firm’s total revenue in a single year.

And what’s more, the signed agreement can be extended by another 18 months. With AstraZeneca aiming to supply those 3bn doses worldwide, this seems quite likely to happen in my mind.

The bottom line

Oxford Biomedica’s revenue from the vaccine may not be sustainable in the future. However, it provides a surge of additional income that will allow it to bolster its LentiVector platform further.

For that reason, even at its current valuation, the stock looks cheap in my eyes, given its potential to shape the drug development industry’s future.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian owns shares in Oxford Biomedica. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Would a stock market crash matter?

Christopher Ruane explains why a stock market crash could turn out to be positive, not negative, for a private investor…

Read more »

Investing Articles

Has the Rolls-Royce share price peaked?

After a strong 2023 performance and (so far) in 2024, the Rolls-Royce share price has stuttered in recent days. Christopher…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Turning a £20k ISA into a £13,900 yearly second income? It’s possible!

By investing a £20k ISA now using certain basic principles, our writer thinks he could set up a second income…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

With no savings, I’d follow Warren Buffett’s number one rule to build wealth

Can this one piece of Warren Buffett wisdom really help our writer as he aims to build wealth in the…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

A second income of £1k a month from just £10 a day! How would I do that?

Mark David Hartley considers how to build a second income stream starting from just £10 a day. Is £1,000 a…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Turn £8,900 into a £24k annual passive income? Here’s how!

Christopher Ruane applies some investing lessons from billionaire Warren Buffett when explaining how he'd aim to earn sizeable passive income…

Read more »

Young Caucasian woman holding up four fingers
Investing Articles

7%+ dividend yields! 4 FTSE 100 shares for investors to consider buying in April

These FTSE shares offer dividend yields comfortably above the index average of 3.7%. Here's why they could be good passive…

Read more »

Dividend Shares

£10k in an ISA? Here’s how to generate a ton of passive income

Passive income can provide a lot more financial freedom and security. Here’s an easy way to generate some within an…

Read more »